Dr. Tina Sampalis has been appointed Medical Science Liaison for Neptune Biotech. This is a transition from her previous position of Chief Global Strategic Officer for Neptune to more of a consulting role.
A biotechnology company from Laval, Québec, Neptune has developed a patented process of extracting oils from Antarctic krill, and these marine-derived omega-3 polyunsaturated fatty acids (”PUFAs”) are commercialized mostly as dietary supplements under private labels in global nutraceutical markets.
Through its subsidiaries, Acasti Pharma Inc. (“Acasti”) and NeuroBioPharm Inc. (“NeuroBio”), Neptune is focusing on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions.
“On behalf of the Board and Management team of Neptune and Acasti, I would like to thank Tina for her leadership and service over the years,” said Mr. Pierre Fitzgibbon, Chairman of Neptune’s Board of Directors and Acasti Board member. “Tina made an important contribution to our success and we look forward to her continued guidance in her new role.”
